Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_4
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Recruiting2
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 42 (100.0%)

Trials by Status

not_yet_recruiting125%
unknown125%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
not_yet_recruitingphase_4

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

NCT07018206
recruitingphase_4

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

NCT06454188
recruiting

Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.

NCT06630715
unknown

Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

NCT04530305

Clinical Trials (4)

Showing 4 of 4 trials
NCT07018206Phase 4

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

Not Yet Recruiting
NCT06454188Phase 4

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

Recruiting
NCT06630715

Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.

Recruiting
NCT04530305

Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4